Low-grade gliomas: The debate continues

Current Oncology Reports

Volumn 8, Issue 1, 2006, Pages 71-77

  Brown, Paul D ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GLIOMA; HAIR LOSS; HUMAN; LOW DRUG DOSE; MALIGNANT TRANSFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PROGNOSIS; RADIATION DOSE; RADIATION HAZARD; RADIATION NECROSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 31544458679     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0012-x     Document Type: Review

References (54)

1. Kleihues P, Cavenee WK: Pathology and Genetics of Tumors of the Nervous System: WHO classification of Tumours. Lyon: IARC Press; 2000.
2. Shaw EG, Scheithauer BW, O'Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J Neurooncol 1997, 31:273-278.
3. Brown PD, Buckner JC, O'Fallon JR, et al.: Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 2004, 59:117-125.
4. Shaw E, Arusell R, Scheithauer B, et al.: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. [see comments]. J Clin Oncol 2002, 20:2267-2276.
5. Okamoto Y, Di Patre PL, Burkhard C, et al.: Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neurophathol 2004, 108:49-56.
6. Cairncross G, Macdonald D, Ludwin S, et al.: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994, 12:2013-2021.
7. Hoang-Xuan K, Capelle L, Kujas M, et al.: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004, 22:3133-3138.
8. Buckner JC, Ballman KV, Scheithauer BW, et al.: Diagnostic and prognostic significance of ip and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma [abstract]. Proc ASCO 2005, 24:1502.
9. Esteller M, Garcia-Foncillas J, Andion E, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. [see comment] [erratum appears in N Engl J Med 2000 Dec 7;343(23):1740]. N Engl J Med 2000, 343:1350-1354.
10. Komine C, Watanabe T, Katayama Y, et al.: Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003, 13:176-184.
11. Connor SE, Gunny R, Hampton T, et al.: Magnetic resonance image registration and subtraction in the assessment of minor changes in low grade glioma volume. Eur Radiol 2004, 14:2061-2066.
12. Jenkinson MD, Smith T, Joyce K, et al.: MRS of oligodendroglial tumors. Neurology 2005, 64:2085-2089.
13. Hakyemez B, Erdogan C, Ercan I, et al.: High-grade and low-grade gliomas: differentiation by using perfusion MR imaging. Clin Radiol 2005, 60:493-502.
14. Giammarile F, Cinotti LE, Jouvet A, et al.: High and low grade oligodendrogliomas (ODG): correlation of aminoacid and glucose uptakes using PET and histological classifications. J Neurooncol 2004, 68:263-274.
15. Surma-aho O, Niemela M, Vilkki J, et al.: Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 2001, 56:1285-1290.
16. Shaw EG, Won M, Brachman D, et al.: Preliminary results of RTOG Protocol 9802: A phase II study of observation in completely resected adult low-grade glioma. Presented at World Federation of Neuro-Oncology. Edinburgh, Scotland; 2005.
17. van den Bent M, Afra D, De Witte O, et al.: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendrogliglioma in adults: the EORTC 22845 randomised trial. Lancet, 2005, 366:985-990.
18. Kondziolka D, Lunsford LID, Martinez AJ: Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 1993, 79:533-536.
19. Recht LD, Lew R, Smith TW: Suspected low-grade glioma: is deferring treatment safe? [see comments]. Ann Neurol 1992, 31:431-436.
20. Reijneveld JC, Sitskoorn MM, Klein M, et al.: Cognitive status and quality of life in patients with suspected versus proven low-grade gliomas. Neurology 2001, 56:618-623.
21. Karim AB, Maat B, Hatlevoll R, et al.: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996, 36:549-556.
22. Florell RC, Macdonald DR, Irish WD, et al.: Selection bias, survival, and brachytherapy for glioma. [erratum appears in J Neurosurg 1992 Sep;77(3):489]. J Neurosurg 1992, 76:179-183.
23. Duffau H, Lopes M, Arthuis F, et al.: Contribution of intraoperative electrical stimulations in surgery of low grade gliomas: a comparative study between two series without (1985-96) and with (1996-2003) functional mapping in the same institution. J Neurol Neurosurg Psychiatry 2005, 76:845-851.
24. Claus EB, Horlacher A, Hsu L, et al.: Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 2005, 103:1227-1233.
25. Karim AB, Afra D, Cornu P, et al.: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002, 52:316-324.
26. Kortmann RD, Jeremic B, Weller M, et al.: Immediate postoperative radiotherapy or "watch and wait" in the management of adult low-grade glioma? Strahlentherapie und Onkologie 2004, 180:408-418.
27. Sofietti R, Borgognone M, Ducati A, et al.: Efficacy of radiation therapy on seizures in low-grade astrocytomas [abstract 422]. Presented at World Federation of Neuro-Oncology. Edinburgh; 2005:111.
28. Reichenthal E, Feldman Z, Cohen ML: Hemispheric supratentorial low-grade astrocytomas. Neurochirurgia 1992, 35:18-22.
29. Kelly PJ, Daumas-Duport C, Scheithauer BW: Stereotactic histologic correlations of computed tomography and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62:450-459.
30. Marcus KJ, Goumnerova L, Billett AL, et al.: Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Physics 2005, 61:374-379.
31. Sheline GE, Wara WM, Smith V: Therapeutic irradiation in brain injury. Int J Radiat Oncol Biol Physics 1980, 6:1215-1228.
32. Brown PD, Buckner JC, Uhm JH, et al.: The neurocognitive effects of radiation in adult low-grade glioma patients. Neuro-Oncology 2003, 5:161-167.
33. Klein M, Heimans JJ, Aaronson NK, et al.: Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002, 360:1361-1368.
34. Swennen MH, Bromberg JE, Witkamp TD, et al.: Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neurooncol 2004, 66:333-339.
35. Kleinberg L, Wallner K, Malkin MG: Good performance status of long-term disease-free survivors of intracranial gliomas [published erratum appears in Int J Radiat Oncol Biol Phys 1993 Jun 15;26(3):563] [see comments]. Int J Radiat Oncol Biol Physics 2 1993, 6:129-133.
36. Gregor A, Cull A, Traynor E, et al.: Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol 1996, 41:55-59.
37. Curnes JT, Laster DW, Ball MR, et al.: MRI of radiation injury to the brain. AJR Am J Roentgenol 1986, 147:119-124.
38. Scheibel RS, Meyers CA, Levin VA: Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol 1996, 30:61-69.
39. Imperato JP, Paleologos NA, Vick NA: Effects of treatment on long-term survivors with malignant astrocytomas [see comment]. Ann Neurol 1990, 28:818-822.
40. Laack NN, Brown PD: Cognitive sequelae of brain radiation in adults. Semin Oncol 2004, 31:702-713.
41. Laack N, Brown P, Furth A, et al.: Neurocognitive function after radiotherapy (RT) for supratentorial low-grade gliomas (LGG): results of a North Central Cancer Treatment Group (NCCTG) prospective study [abstract 18]. Int J Radiat Oncol Biol Phys 2003, 57:134.
42. Armstrong CL, Hunter JV, Ledakis GE, et al.: Late cognitive and radiographic changes related to radiotherapy: initial prospective findings [see comments]. Neurology 2002, 59:40-48.
43. Vigliani MC, Sichez N, Poisson M, et al.: A prospective study of cognitive functions following conventional radiotherapy for supratentorial gliomas in young adults: 4-year results. Int J Radiat Oncol Biol Phys 1996, 35:527-533.
44. Torres IJ, Mundt AJ, Sweeney PJ, et al.: A longitudinal neuropsychological study of partial brain radiation in adults with brain tumors. Neurology 2003, 60:1113-1118.
45. Hirsch J-F, Sainte Rose C, Pierre-Kahn A: Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989, 70:568-572.
46. Eyre HJ, Crowley JJ, Townsend JJ, et al.: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993, 78:909-914.
47. Buckner JC, Gesme D, Mallon JR, et al.: Phase II trial of procarbazine, lornustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003, 21:251-255.
48. Pace A, Vidiri A, Galie E, et al.: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response [see comment]. Ann Oncol 2003, 14:1722-1726.
49. Quinn JA, Reardon DA, Friedman AH, et al.: Phase II trial of temozolomide in patients with progressive low-grade glioma [see comment]. J Clin Oncol 2003, 21:646-651.
50. Brada M, Viviers L, Abson C, et al.: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas [see comment]. Ann Oncol 2003, 14:1715-1721.
51. Brown P, Buckner J: Temozolomide: too early for definitive conclusions. J Clin Oncol 2003, 21:3710.
52. Stupp R, Mason WP, van den Bent M, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
53. Pignatti F, van den Bent M, Curran D, et al.: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002, 20:2076-2084.
54. Buckner JC, Burch PA, Schaefer PL, et al.: Phase II trial of nitrogen mustard, vincristine, and procarbazine (MOP) in patients with recurrent glioma: NCCTG results [abstract]. Proc ASCO 1996, 25:283.